



MINUTES

Utah Department of Health
Drug Utilization Review Board

**Thursday, February 9th, 2017
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125**

Board Members Present:

Jennifer Brinton, M.D., Board Chair
Neal Catalano, Pharm.D.
Aesha Drozdowski, Pharm.D.
Steve Lore, M.D.
Kim Michelson, D.D.S.
Keith Tolman, M.D.
Kumar Shah, M.Sc., P.Eng.
Katherine Smith, Pharm.D.
Michael Symond, M.D.
Sharon Weinstein, M.D.

Board Members Excused:

Ben Berrett, Pharm.D.
Holly Gurgle, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, Pharm D.
Bryan Larson, Pharm.D
Robyn Seely, Pharm D.
Susan Siegfried, M.D
Merelynn Berrett, R.N
Alyssa Pitts, R.N.
Heather Santacruz, R.N.

Other Individuals Present:

Joann LeFleur, UofU*
Valeria Gonzales, UofU*
Vicki Frydrych, UofU*
*UofU = University of Utah

Meeting conducted by: Jennifer Brinton, M.D.

1. **Welcome & Housekeeping:** Jennifer Brinton, M.D. opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of January Minutes:** Kumar Shah, M.Sc., P.Eng. made a motion to approve the minutes from January. Neal Catalano, Pharm.D. seconded the motion. Keith Tolman abstained, otherwise unanimous.

3. **Pharmacy & Therapeutics Committee Update**.....Bryan Larson, Pharm.D.
 - a. January's topic was combination opioid products
 - b. February's meeting is canceled, next meeting March 16th, 2017
4. **Reconsideration of PA criteria: Xanax XR**.....Robyn Seely Pharm.D.
 - a. Susan Siegfried M.D. presented clinical rationale
 - b. Motion to remove clinical Prior Authorization (PA) criteria from Xanax XR by Mike Symond M.D., seconded by Neal Catalano Pharm.D., unanimous approval.
5. **9 Month Review: Xyrem**.....Robyn Seely, Pharm.D.
 - a. Motion to keep the clinical PA on Xyrem by Steve Lore, M.D., seconded Neal Catalano Pharm.D., unanimous approval.
6. **Long Acting Blood Factors**.....Valerie Gonzales Pharm.D.
 - a. **Public Comment**
 1. Trina Barrett, Bayer, Kovaltry
 - b. **Board Discussion**
 1. Robyn Seely Pharm.D. provided background information regarding Utah Medicaid's contract with a hemophilia care provider and the average number of Utah Medicaid patients in the program at any given time.
 2. According to the most recent data, two patients had been prescribed Eloctate, neither patient had been compliant with shorter acting blood factors and were not compliant with Eloctate.
 3. The guidelines included in the University's report were discussed.
 - c. **Motions**
 1. Motion to put no PA criteria on long acting blood factors by Keith Tolman, M.D., seconded by Kim Michaelson, D.D.S., Neal Catalano abstained, otherwise unanimous approval.
 2. Motion to suggest that the Pharmacy and Therapeutics Committee review long acting blood factors by Mike Symond M.D., seconded by Steve Lore M.D., unanimous approval.
7. **Public Meeting Adjourned**
8. **The next meeting is scheduled for March 9th, 2017.**

Audio recordings of DUR meetings are available online at:
[https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR Board Audio Recordings/](https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/)